HER2-NEGATIVE BREAST CARCINOMA
Clinical trials for HER2-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop High-Risk breast cancer from coming back
Disease control Recruiting nowThis phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Could a pill replace chemo for some breast cancers? major trial launches
Disease control Recruiting nowThis study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Texts and smart gadget aim to boost cancer pill adherence
Disease control Recruiting nowThis study tests a system called CONCURxP that uses a smart pill dispenser (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills as prescribed. About 410 patients will be split into two groups: one gets the full system…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can Pre-Surgery hormone therapy help lobular breast cancer patients?
Disease control Recruiting nowThis study looks at whether giving hormone therapy before breast-conserving surgery helps reduce leftover cancer cells at the edges of removed tissue. It involves 176 postmenopausal women with stage 2-3 ER+/HER2- invasive lobular carcinoma. The goal is to see if this approach lea…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy for breast cancer bone metastases enters human testing
Disease control Recruiting nowThis early-stage trial tests the drug abemaciclib (a CDK4/6 inhibitor) given together with targeted radiation for people with metastatic HR+ HER2- breast cancer that has spread to bone. The main goal is to find the safest dose of abemaciclib when combined with radiation. About 28…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can adding radiation to immunotherapy and chemotherapy boost breast cancer treatment?
Disease control Recruiting nowThis phase 2 trial is testing whether adding low or high dose radiation to standard chemotherapy and the immunotherapy drug pembrolizumab can improve treatment for people with node-positive triple negative breast cancer. Thirty-two participants will be randomly assigned to receiv…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could less chemo be better for older breast cancer patients?
Disease control Recruiting nowThis study looks at whether giving a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) can work well and cause fewer side effects in women aged 65 and older with early-stage HER2-negative breast cancer. The goal is to help these women complete their treatment …
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could a common mushroom help fight breast cancer? new trial investigates
Disease control Recruiting nowThis phase 2 trial is testing whether turkey tail mushroom extract can slow or shrink estrogen receptor-positive, HER2-negative breast cancer in post-menopausal women. Forty participants will take the supplement between diagnosis and surgery, and researchers will measure changes …
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control Recruiting nowThis study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental combo aims to overcome drug resistance in metastatic cancers
Disease control Recruiting nowThis early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Stress-Busting program tested for triple negative breast cancer
Symptom relief Recruiting nowThis study tests whether a 10-week stress reduction program is doable and helpful for people with triple negative breast cancer. The program includes relaxation, coping skills, and social support, and also addresses basic needs like utilities or transportation. Researchers will m…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Acupuncture may help black women avoid debilitating joint pain during breast cancer treatment
Symptom relief Recruiting nowThis study tests whether in-person acupuncture or virtual acupressure can prevent joint pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. It focuses on Non-Hispanic Black women with early-stage breast cancer, who are more likely to stop treatment du…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Blood test may spot breast cancer resistance before It's too late
Knowledge-focused Recruiting nowThis study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is …
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Real-World study tracks ADC effectiveness in advanced breast cancer
Knowledge-focused Recruiting nowThis study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…
Matched conditions: HER2-NEGATIVE BREAST CARCINOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC